Tezacaftor and ivacaftor for the treatment of cystic fibrosis

被引:14
|
作者
Paterson, Sarah L. [1 ,2 ]
Barry, Peter J. [1 ,2 ]
Horsley, Alexander R. [1 ,2 ]
机构
[1] Manchester NHS Fdn Trust, Wythenshawe Hosp, Manchester Adult Cyst Fibrosis Ctr, Southmoor Rd, Wythenshawe M23 9LT, England
[2] Univ Manchester, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Manchester, Lancs, England
关键词
Cystic fibrosis; CFTR; Ivacaftor; Lumacaftor; tezacaftor; PHE508DEL CFTR MUTATION; CLINICAL-TRIAL; LUMACAFTOR/IVACAFTOR; EFFICACY; SAFETY; F508DEL-CFTR; POTENTIATOR; COMBINATION; PHASE-3; INITIATION;
D O I
10.1080/17476348.2020.1682998
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: Cystic fibrosis (CF) is a complex, multi-system, genetic disease affecting over 70,000 people worldwide. The underlying defect is a mutation in the CFTR gene. Dysfunctional CFTR protein results in abnormal anion movement across epithelial membranes in affected organs. There has been a paradigm shift in CF treatment over the last decade with the advent of CFTR modulation, treatments which target this underlying genetic defect and have the potential to change the course of CF clinical disease. Areas covered: Available CFTR modulators in current clinical practice are reviewed in this article, with a direct comparison and summary of relevant pivotal clinical trials. The approval of ivacaftor and subsequent development of lumacaftor and tezacaftor dual combinations represents an exciting development in CF management in recent years. Expert opinion: Tezacaftor/ivacaftor (tez/iva) appears to have a more favorable adverse event and drug-drug interaction profile than lumacaftor/ivacaftor. Tez/iva has been approved, alongside Phe508del, for a large number of 'residual function' CFTR mutations, with some based on response to in vitro culture. Dual therapy with tez/iva has paved the way for triple CFTR modulation currently in clinical trials with an ultimate view to provide modulation therapy to the majority of CF genotypes in the future.
引用
收藏
页码:15 / 30
页数:16
相关论文
共 50 条
  • [1] Tezacaftor/Ivacaftor (Symdeko) for Cystic Fibrosis
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1558): : 174 - 176
  • [2] Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1589): : 5 - 7
  • [3] Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
    Shiferaw, Dejene
    Faruqi, Shoaib
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 1029 - 1040
  • [4] Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis
    De Vuyst, Richard C.
    Bennard, Erin
    Kam, Charissa W.
    McKinzie, Cameron J.
    Esther, Charles R.
    [J]. PEDIATRIC PULMONOLOGY, 2023, 58 (05) : 1592 - 1594
  • [5] Safety and effectiveness of treatment with elexacaftor, tezacaftor and ivacaftor in adults with cystic fibrosis
    Royo, Rosa Nieto
    Barata, Diego Duran
    Barreto, Deisy Barrios
    Franquiz, Winnifer Briceno
    Carro, Luis Maiz
    [J]. MEDICINA CLINICA, 2023, 161 (08): : 338 - 341
  • [6] Cystic Fibrosis: Triple Therapy with Elexacaftor, Tezacaftor and Ivacaftor
    Lorenz, Judith
    [J]. PNEUMOLOGIE, 2022, 76 (03): : 153 - 153
  • [7] The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
    Lommatzsch, Sherstin T.
    Taylor-Cousar, Jennifer L.
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [8] Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
    Zhang, Lijia
    Albon, Dana
    Jones, Marieke
    Bruschwein, Heather
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [9] Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis
    Smith, Megan
    Ryan, Kevin J.
    Gutierrez, Hector
    Sanchez, Luz Helena Gutierrez
    Anderson, Janaina Nogueira
    Acosta, Edward P.
    Benner, Kim W.
    Guimbellot, Jennifer S.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (01) : E8 - E10
  • [10] Effects of elexacaftor-tezacaftor-ivacaftor discontinuation in cystic fibrosis
    Mitropoulou, Georgia
    Balmpouzis, Zisis
    Polojoux, Jerome
    Dotta-Celio, Jennifer
    Sauty, Alain
    Koutsokera, Angela
    [J]. RESPIRATORY MEDICINE AND RESEARCH, 2022, 82